FDA Inspection 1273405 — SERIPHARM
The FDA completed an inspection of SERIPHARM on March 12, 2021 in Le Mans. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- March 12, 2021
- Fiscal Year
- 2021
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Le Mans (France)
Additional Details
Mutual Recognition Agreement (MRA)